Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Intell
Post# of 420
(Total Views: 199)
Posted On: 03/21/2022 3:55:17 PM
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Intellectual Property Portfolio Grows Following Receipt of 24th Granted Patent
- Lexaria has received a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof”
- The new patent, granted in Australia, is the first awarded from Lexaria’s 8th patent family and offers IP protection across a total of 9 claims
- Lexaria believes the patent could be meaningful as it seeks to build value
- With the new patent, Lexaria’s IP portfolio has now grown to 24 granted patents worldwide
In his letter to shareholders dated January 27, 2022, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka documented the company’s expectation that it would receive additional patents in 2022. The expected patents would build on the company’s already solid intellectual property (“IP”) portfolio that expanded severalfold last year when Lexaria was awarded five new patents. The then newly granted patents brought the company’s total to 23 granted patents worldwide as of December 2021 (https://nnw.fm/gQHZ6).
And in an announcement that fulfills part of the company’s expectations for 2022 as well as expands its impressive IP portfolio even further, Lexaria recently reported it had been awarded a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” (https://nnw.fm/iCGI7).
Granted in Australia, the new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine, and other nicotine complexes.
Following the receipt of this most recent patent, which is the first patent awarded from its 8th patent family, Lexaria’s IP portfolio has grown to 24 granted patents; the Australian patent offers IP protection across a total of 9 claims and is set to expire in April 2039. Moreover, according to the company, corresponding patent applications within this patent family are currently pending in other jurisdictions, including the U.S.
Lexaria is a global innovator in drug delivery platforms. Its flagship drug delivery technology, DehydraTECH, has been proven, through animal and human studies, to increase bioavailability, brain absorption, and the speed of onset of active pharmaceutical ingredients, as well as mask their unwanted tastes. In one such animal study — the oral nicotine absorption study NIC-A21-1 — whose results were announced in October last year, Lexaria established that DehydraTECH-processed nicotine delivered through the oral pouch product format “required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls” (https://nnw.fm/0uTQ2).
In earlier studies conducted in 2018, the company also revealed that DehydraTECH improved the peak nicotine delivery as well as the speed at which nicotine was delivered to the bloodstream. Moreover, Lexaria established that DehydraTECH for oral nicotine resulted in higher brain levels of nicotine compared to controls (https://nnw.fm/tW3yj).
The studies and their groundbreaking results demonstrate the company’s progress toward improving oral nicotine products. In this regard, the protection offered by the granted patent, Lexaria believes, could contribute substantially toward the company’s ability to build value.
Speaking during the Benzinga Global Small-Cap Conference held late last year, George Jurcic, Lexaria’s Head of Investor Relations (“IR”), noted that the company already has a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “We have a disruptive drug technology with multiple opportunities for success in cannabinoids, nicotine, antivirals, and other active pharmaceutical ingredients,” said Jurcic (https://nnw.fm/MteDd).
Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria has received a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof”
- The new patent, granted in Australia, is the first awarded from Lexaria’s 8th patent family and offers IP protection across a total of 9 claims
- Lexaria believes the patent could be meaningful as it seeks to build value
- With the new patent, Lexaria’s IP portfolio has now grown to 24 granted patents worldwide
In his letter to shareholders dated January 27, 2022, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka documented the company’s expectation that it would receive additional patents in 2022. The expected patents would build on the company’s already solid intellectual property (“IP”) portfolio that expanded severalfold last year when Lexaria was awarded five new patents. The then newly granted patents brought the company’s total to 23 granted patents worldwide as of December 2021 (https://nnw.fm/gQHZ6).
And in an announcement that fulfills part of the company’s expectations for 2022 as well as expands its impressive IP portfolio even further, Lexaria recently reported it had been awarded a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” (https://nnw.fm/iCGI7).
Granted in Australia, the new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine, and other nicotine complexes.
Following the receipt of this most recent patent, which is the first patent awarded from its 8th patent family, Lexaria’s IP portfolio has grown to 24 granted patents; the Australian patent offers IP protection across a total of 9 claims and is set to expire in April 2039. Moreover, according to the company, corresponding patent applications within this patent family are currently pending in other jurisdictions, including the U.S.
Lexaria is a global innovator in drug delivery platforms. Its flagship drug delivery technology, DehydraTECH, has been proven, through animal and human studies, to increase bioavailability, brain absorption, and the speed of onset of active pharmaceutical ingredients, as well as mask their unwanted tastes. In one such animal study — the oral nicotine absorption study NIC-A21-1 — whose results were announced in October last year, Lexaria established that DehydraTECH-processed nicotine delivered through the oral pouch product format “required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls” (https://nnw.fm/0uTQ2).
In earlier studies conducted in 2018, the company also revealed that DehydraTECH improved the peak nicotine delivery as well as the speed at which nicotine was delivered to the bloodstream. Moreover, Lexaria established that DehydraTECH for oral nicotine resulted in higher brain levels of nicotine compared to controls (https://nnw.fm/tW3yj).
The studies and their groundbreaking results demonstrate the company’s progress toward improving oral nicotine products. In this regard, the protection offered by the granted patent, Lexaria believes, could contribute substantially toward the company’s ability to build value.
Speaking during the Benzinga Global Small-Cap Conference held late last year, George Jurcic, Lexaria’s Head of Investor Relations (“IR”), noted that the company already has a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “We have a disruptive drug technology with multiple opportunities for success in cannabinoids, nicotine, antivirals, and other active pharmaceutical ingredients,” said Jurcic (https://nnw.fm/MteDd).
Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼